Want to see HK:2453 full AI Analyst Report?
2453 Stock Chart & Stats
HK$1.83
-HK$0.24(-2.76%)
At close: 4:00 PM EST
HK$1.83
-HK$0.24(-2.76%)
Day’s Range― - ―
52-Week RangeHK$0.63 - HK$3.28
Previous CloseN/A
Volume2.50M
Average Volume (3M)195.41K
Market Cap
HK$564.24M
Enterprise ValueHK$4.18K
Total Cash (Recent Filing)HK$161.74M
Total Debt (Recent Filing)HK$3.06B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding313,874,630
10 Day Avg. Volume181,300
30 Day Avg. Volume195,406
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe 2025 revenue rebound shows that demand for the company’s oncology-related services and products can recover after volatility. If sustained, stronger top-line activity could improve operating leverage, support investment in hospital projects, and provide a foundation for future earnings improvement.
Gross Margin ImprovementA return to positive gross margin is an important operational improvement because it indicates that revenue is covering direct costs more effectively than in prior periods. Further gains could strengthen the economics of oncology services and equipment distribution, although profitability remains unproven.
Integrated Oncology Revenue ModelThe combination of recurring hospital-based service activity and product-related income gives Concord Healthcare more than one way to monetize its oncology focus. This integrated model can deepen relationships with healthcare providers and align equipment deployment with ongoing clinical operations.
Bears Say
Persistent Operating LossesDeep operating and net losses show that the recent revenue recovery has not yet translated into a viable earnings model. Continued losses can restrict reinvestment, weaken returns on shareholder capital, and require management to improve pricing, utilization, and cost control before profitability becomes durable.
Negative Cash GenerationNegative operating and free cash flow indicate that reported business activity is not currently converting reliably into cash. Persistent cash deficits may increase dependence on external funding and reduce flexibility to finance oncology projects, absorb setbacks, or support growth without additional capital.
Elevated LeverageLeverage remains high relative to the company’s weak profitability and cash generation, even though debt-to-equity improved from about 1.95 times in 2024. This capital structure leaves less room to fund expansion internally and increases the consequences of prolonged losses or uneven cash conversion.
Concord Healthcare Group Co., Ltd. Class H News
2453 FAQ
What was Concord Healthcare Group Co., Ltd. Class H’s price range in the past 12 months?
Concord Healthcare Group Co., Ltd. Class H lowest stock price was HK$0.63 and its highest was HK$3.28 in the past 12 months.
What is Concord Healthcare Group Co., Ltd. Class H’s market cap?
Concord Healthcare Group Co., Ltd. Class H’s market cap is HK$564.24M.
When is Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date?
Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 191 days.
How were Concord Healthcare Group Co., Ltd. Class H’s earnings last quarter?
Concord Healthcare Group Co., Ltd. Class H released its earnings results on Aug 21, 2026. The company reported -HK$0.112 earnings per share for the quarter.
Is Concord Healthcare Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Concord Healthcare Group Co., Ltd. Class H’s price is currently Overvalued.
Does Concord Healthcare Group Co., Ltd. Class H pay dividends?
Concord Healthcare Group Co., Ltd. Class H does not currently pay dividends.
What is Concord Healthcare Group Co., Ltd. Class H’s EPS estimate?
Concord Healthcare Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Healthcare Group Co., Ltd. Class H have?
Concord Healthcare Group Co., Ltd. Class H has 313,874,630 shares outstanding.
What happened to Concord Healthcare Group Co., Ltd. Class H’s price movement after its last earnings report?
Concord Healthcare Group Co., Ltd. Class H reported an EPS of -HK$0.112 in its last earnings report. Following the earnings report the stock price went up 2.907%.
Which hedge fund is a major shareholder of Concord Healthcare Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2453
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Concord Healthcare Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Technical Analysis
C-MER Eye Care Holdings Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―